Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James R. O’dell; Stanley B. Cohen; J. Carter Thorne; Joel Kremer

doi:10.2147/OARRR.S169152

Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

James R. O’dell, Stanley B. Cohen, J. Carter Thorne, Joel Kremer

Research output: Contribution to journal › Article

Abstract

Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

Original language	English (US)
Pages (from-to)	97-101
Number of pages	5
Journal	Open Access Rheumatology: Research and Reviews
Volume	10
DOIs	https://doi.org/10.2147/OARRR.S169152
State	Published - 2018

Keywords

Biologic
Claims
Methotrexate
Tumor necrosis factor

ASJC Scopus subject areas

Rheumatology

Access to Document

10.2147/OARRR.S169152

Fingerprint Dive into the research topics of 'Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate'. Together they form a unique fingerprint.

Cite this

O’dell, J. R., Cohen, S. B., Carter Thorne, J., & Kremer, J. (2018). Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. Open Access Rheumatology: Research and Reviews, 10, 97-101. https://doi.org/10.2147/OARRR.S169152

@article{774421c81dd649d2ab3dd9e9eae2b63f,

title = "Treatment of rheumatoid arthritis in the USA: Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate",

abstract = "Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.",

keywords = "Biologic, Claims, Methotrexate, Tumor necrosis factor",

author = "O{\textquoteright}dell, {James R.} and Cohen, {Stanley B.} and {Carter Thorne}, J. and Joel Kremer",

year = "2018",

doi = "10.2147/OARRR.S169152",

language = "English (US)",

volume = "10",

pages = "97--101",

journal = "Open Access Rheumatology: Research and Reviews",

issn = "1179-156X",

publisher = "Dove Medical Press Limited",

}

TY - JOUR

T1 - Treatment of rheumatoid arthritis in the USA

T2 - Premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

AU - O’dell, James R.

AU - Cohen, Stanley B.

AU - Carter Thorne, J.

AU - Kremer, Joel

PY - 2018

Y1 - 2018

N2 - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

AB - Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort). Conclusion: MTX is underused in the treatment of RA in the USA.

KW - Biologic

KW - Claims

KW - Methotrexate

KW - Tumor necrosis factor

UR - http://www.scopus.com/inward/record.url?scp=85064749103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064749103&partnerID=8YFLogxK

U2 - 10.2147/OARRR.S169152

DO - 10.2147/OARRR.S169152

M3 - Article

C2 - 30013407

AN - SCOPUS:85064749103

VL - 10

SP - 97

EP - 101

JO - Open Access Rheumatology: Research and Reviews

JF - Open Access Rheumatology: Research and Reviews

SN - 1179-156X

ER -